Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
60-Word AI Digest
Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals. Reporting by CNBC highlights major developments in this space as key stakeholders evaluate broader implications. Further data and contextual analysis are actively being published. Access the full coverage dispatch below for complete documentation.
Key Takeaways
- Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
- Western biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer.
- Click full coverage link below for the complete official dispatch.
Western biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer.
Original Publisher Attribution
This summary was curated from CNBC.